Research
Private investment in longevity biotech surged 220% to $8.49 billion in 2024—almost entirely US-based and venture-backed—while NIH allocates only 0.8% of its budget to aging biology despite aging driving over 80% of US deaths, and no randomized controlled trial has yet demonstrated that any geroscience intervention extends human healthspan at population scale. The central unresolved tension is whether targeting aging biology directly outperforms disease-specific research and primary care investment as a resource allocation strategy, with geroscience advocates citing multi-trillion-dollar economic returns and critics—including Global South institutions and structural-inequality scholars—arguing that basic care and social determinants deliver comparable healthspan gains more cheaply and equitably. The investment geography itself may be the sharpest policy question: with populations bearing the greatest age-related burden almost entirely excluded from a field dominated by US venture capital, the briefing cannot resolve whether current longevity science will compress health inequality or entrench it.
In 2024, global investment in longevity companies surged to $8.49 billion, marking a substantial 220% increase from the previous year,
In this review, we present the senolytic drugs as a promising way to treat age-related diseases but also their limitations during clinical development.
Research Recommendations for Cardiovascular Aging Research. ... budget and duration in relation to the proposed research; o Adequacy of the ...
In 2021, the global population aged 70 and older reached 494.4 (95%UI 482.1–508.2) million. Death and DALY rates have declined by 9.2% (95%CI ...
These hallmarks are: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, ...
... targeted at mechanisms of aging itself. This page provides FDA policies and best practices for geroscience-related drug development.
Altos Labs raised initial funding from renowned company builders and investors, including ARCH Venture Partners.
UNITY Biotechnology was one of the first senolytics companies, and now conducts clinical trials of small molecule senolytic therapies.
This article proposes a roadmap outlining the critical milestones necessary to advance longevity interventions from research to clinical readiness.
Since we are already so long lived, even a 30% increase in healthy life span will give the first beneficiaries of rejuvenation therapies another 20 years—an ...
NIA prepares an annual Congressional Budget Justification, which provides the Senate and House Appropriations Committees with detailed estimates and ...
This document describes the plan for a Decade of Healthy Ageing 2021–2030, which will consist of 10 years of concerted, catalytic, sustained collaboration.
Globally, the number of persons aged 80 or over is projected to triple by 2050, from 137 million in 2017 to 425 million in 2050. By 2100 it is expected to ...
A randomized, double-blind, placebo-controlled trial assessing the effects of low and high doses of intermittent Rapamycin on a weekly schedule.
Research Centers (-$74.9 million; total $230.6 million):. NIA will award a total of 142 Research Centers Grants, flat to FY 2025. This allows NIA to fund ...
A coordinated public health approach is essential to promote healthy aging and mitigate the economic and societal impacts of population aging.
The panelists discussed what can be learned from the reform efforts of the 1990s, and address the question of whether, and in what political environment, ...
# The Global Roadmap for Healthy Longevity Lives of good health, function, meaning, purpose, and dignity are achievable—now is the time to seize this opportunity and begin working toward a better future for all.
Geroscience posits that cardiovascular disease (CVD) and other chronic diseases result from progressive erosion of the effectiveness of homeostatic mechanisms.
Sign up to read the full research briefing
Sign up